Use of IL-1 β, IL-6, TNF-α, and MMP-8 biomarkers to distinguish peri-implant diseases: A systematic review and meta-analysis.

Abstract

To investigate the use of peri-implant crevicular fluid (PICF) interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α), and matrix metalloproteinase-8 (MMP-8) biomarkers in distinguishing between healthy implants (H), peri-implant mucositis (MU), and peri-implantitis (PI). Electronic using three databases (Pubmed, EMBASE, and Cochrane) and manual searches were conducted for articles published up to March 2018 by two independent calibrated reviewers. Meta-analyses using a random-effects model were conducted for each of the cytokines; IL-1β, IL-6, and TNF-α, to analyze standardized mean difference (SMD) between H and MU, MU and PI, H and PI with their associated 95% confidence intervals (CI). Qualitative assessment of MMP-8 was provided consequent to the lack of studies that provide valid data for a meta-analysis. Nineteen articles were included in this review. IL-1β, IL-6, and TNF-α, levels were significantly higher in MU than H groups (SMD: 1.94; 95% CI: 0.87, 3.35; P < .001, SMD: 1.17; 95% CI: 0.16, 3.19; P = .031 and SMD: 3.91; 95% CI: 1.13, 6.70; P = .006, respectively). Similar results were obtained with PI compared to H sites (SMD: 2.21, 95% CI: 1.32, 3.11; P < .001, SMD: 1.72; 95% CI: 0.56, 2.87; P = .004 and SMD: 3.78; 95% CI: 1.67, 5.89; P < .001, respectively). IL-6 was statistically higher in PI than MU sites (SMD = 1.46; 95% CI: 0.36, 2.55; P = .009); while IL-1ß increase was not significant. Despite absence of meta-analysis, MMP-8 show to be a promising biomarker in detection of PI in literature. Within the limitations of this study, pro-inflammatory cytokines in PICF, such as IL-1ß and IL-6, can be used as adjunct tools to clinical parameters to differentiate H from MU and PI.